Explore another way you may receive treatment.

Potential OPDIVO® (nivolumab) user gifting his wife a mug.
Potential OPDIVO® (nivolumab) user gifting his wife a mug.

Clinical trial results
for previously
treated advanced
kidney cancer

For certain adults with previously treated advanced
kidney cancer (renal cell carinoma)

Actor portrayals.

An FDA-approved immunotherapy that helped people live longer compared to everolimus

About the clinical trial

In a clinical trial of 821 people with previously treated advanced kidney cancer, 410 people were given OPDIVO and 411 people were given everolimus, a standard treatment.

People given OPDIVO lived longer compared to everolimus

At 25 months, half the people given OPDIVO® were alive.
OPDIVO

Half the people were alive

At 20 months, half the people given everolimus were alive.
Everolimus

Half the people were alive

In a clinical trial, people given OPDIVO had a 27% lower risk of dying than those given everolimus.

More people given OPDIVO saw their tumors shrink or disappear completely
compared to everolimus

22% of people given OPDIVO® for previously treated RCC had their tumors shrink or disappear completely versus 4% of people given everolimus.

In a clinical trial, tumors shrinking or disappearing completely because of treatment is known as the overall response rate.
 

Words to know

Overall response rate is the percentage of patients who responded to treatment. These patients saw their tumors either shrink or disappear completely.

OPDIVO will not work for everyone. Individual results may vary.

OPDIVO Qvantig may be a faster* way to receive treatment.

It is not known if OPDIVO Qvantig is safe and effective in children. OPDIVO Qvantig cannot be used in combination with ipilimumab.
*A 3-5 minute injection time of OPDIVO Qvantig compared to a 30-minute infusion time of OPDIVO. This does not account for all aspects of treatment. Does not include observation time. Actual clinic time may vary.

Timer icon indicating the injection of OPDIVO® QVANTIG™ takes 3-5 minutes.
Hands exploring how OPDIVO® (nivolumab) works and learning how this treatment may help fight cancer.

How treatment works

See how this treatment may help your body fight cancer

OPDIVO® (nivolumab) side effects.

Side effects

View side effects of treatment and learn how to manage them

See treatment plans and what to expect from an OPDIVO® IV infusion or OPDIVO® QVANTIG™ subcutaneous injection.

Getting treatment

See treatment plans and what to expect from an intravenous (IV) infusion or under-the-skin injection (subcutaneous injection)

For adults with previously treated advanced kidney cancer (renal cell carcinoma)

As an intravenous infusion

OPDIVO® (nivolumab) is a prescription medicine used to treat adults with kidney cancer (renal cell carcinoma) when your cancer has spread after treatment with other cancer medications.

It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.

It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.

For subcutaneous injection

OPDIVO Qvantig™ (nivolumab + hyaluronidase-nvhy) is a prescription medicine used to treat adults with kidney cancer (renal cell carcinoma) when your cancer has spread after treatment with other cancer medications.

It is not known if OPDIVO Qvantig is safe and effective in children.



466-US-2500012   04/25